NYSE: EHCEncompass Health Corp Stock
$122.21-0.55 (-0.45%)
Updated Sep 23, 2026
EHC Price
$122.21
Fair Value Price
N/A
Market Cap
$12.06B
52 Week Low
$92.77
52 Week High
$127.99
P/E
19.65x
P/B
4.64x
P/S
1.61x
PEG
3.35x
Dividend Yield
0.62%
Revenue
$6.21B
Earnings
$621.00M
Gross Margin
27.5%
Operating Margin
15.42%
Profit Margin
10%
Debt to Equity
1.54
Operating Cash Flow
$1B
Beta
0.55
Next Earnings
Nov 4, 2026
Ex-Dividend
Oct 1, 2026
Next Dividend
Oct 15, 2026
EHC Overview
Encompass Health Corporation offers facility-based and home-based post-acute services through a network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. Known as Amcare, Inc. until 2018, the company was incorporated in 1984 and is based in Birmingham, AL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EHC's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +17.17% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
EHC
Ranked#16 of 42
Ranked#16 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.86 | A | |
| $256.44 | A | |
| $5.15 | B |
Be the first to know about important EHC news, forecast changes, insider trades & much more!
EHC News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EHC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EHC ($122.21) is trading above its intrinsic value of $40.80, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EHC is good value based on its earnings relative to its share price (19.65x), compared to the US market average (48.4x)
P/E vs Market Valuation
EHC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more EHC due diligence checks available for Premium users.
Valuation
EHC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
19.65x
Industry
15.93x
Market
48.4x
EHC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EHC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
EHC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.64x
Industry
5.56x
EHC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EHC price to earnings growth (PEG)
For valuing profitable companies with growth potential
EHC is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
EHC's financial health
Profit margin
Revenue
$1.6B
Net Income
$153.9M
Profit Margin
9.6%
EHC's Earnings (EBIT) of $956.90M... subscribe to Premium to read more.
Interest Coverage Financials
EHC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.5B
Liabilities
$4.0B
Debt to equity
1.54
EHC's short-term assets ($1.04B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EHC's long-term liabilities ($3.12B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EHC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EHC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$282.6M
Investing
-$235.6M
Financing
-$76.9M
EHC's operating cash flow ($1.21B)... subscribe to Premium to read more.
Debt Coverage Financials
EHC vs Medical Care Facility Stocks
Encompass Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.